---

CEO, Veranova

Mike Riley assumed the role of Veranova's CEO in May 2023, bringing more than 20 years of experience in pharmaceutical contract development and manufacturing operations. In a former role as president of Catalent’s Biotherapeutics business, Riley managed a unit with more than 6,500 employees and revenue exceeding $1 billion. At Veranova, his expertise has positioned the company for sustained growth in high-potential areas such as personalized and targeted therapies, encompassing ADCs, protein degraders, highly potent APIs and other complex synthetic modalities. His appointments to the Veranova Scientific Advisory Board include 2022 Nobel Prize Laureate Carolyn Bertozzi. 

“People need to know that you mean what you say, that you will follow through on your commitments, and that you will always seek to make the right ethical decision. Demonstrating that level of integrity in both words and actions sets the right example for your people.”